25- Regulation of Coronary Blood Flow Flashcards
acebutolol (Sectral)
Cardioselective- B1 selective antagonist
- blocks B1 receptors on myocardium and sinus node (can also dec. renin secretion)
- causes dec. HR and contractility
- used in CAD without signs of acute HF
- in combo with nitrates
- prolong survival in compensated HF d/t reduction of MVO2
- negative inotropic effects may worsen HF
- start with low dose and titrate slowly; rebound phenomenon if d/c’d abruptly d/t B1 receptor upregulation can cause unstable angina or MI (need to taper dosing)
- S/Fx: bronchospasm (avoid in asthmatics), poor outcomes: inc. Type II diabetes, hypoglycemia, hyperlipidemia, myocardial depression, bradycardia, reduced exercise tolerance, sleep disturbance and cold extremeties, impotence
- Contraindicated in: severe asthma, bradycardia, AV blockade, severe PVD, insulin dependent DM, Prinzmetal’s angina (may inc. vasospasm)
atenolol (Tenormin)
Cardioselective- B1 selective antagonist
- blocks B1 receptors on myocardium and sinus node (can also dec. renin secretion)
- causes dec. HR and contractility
- used in CAD without signs of acute HF
- in combo with nitrates
- prolong survival in compensated HF d/t reduction of MVO2
- negative inotropic effects may worsen HF
- start with low dose and titrate slowly; rebound phenomenon if d/c’d abruptly d/t B1 receptor upregulation can cause unstable angina or MI (need to taper dosing)
- S/Fx: bronchospasm (avoid in asthmatics), poor outcomes: inc. Type II diabetes, hypoglycemia, hyperlipidemia, myocardial depression, bradycardia, reduced exercise tolerance, sleep disturbance and cold extremeties, impotence
- Contraindicated in: severe asthma, bradycardia, AV blockade, severe PVD, insulin dependent DM, Prinzmetal’s angina (may inc. vasospasm)
metoprolol (Lopressor)
Cardioselective- B1 selective antagonist
- blocks B1 receptors on myocardium and sinus node (can also dec. renin secretion)
- causes dec. HR and contractility
- used in CAD without signs of acute HF
- in combo with nitrates
- prolong survival in compensated HF d/t reduction of MVO2
- negative inotropic effects may worsen HF
- start with low dose and titrate slowly; rebound phenomenon if d/c’d abruptly d/t B1 receptor upregulation can cause unstable angina or MI (need to taper dosing)
- S/Fx: bronchospasm (avoid in asthmatics), poor outcomes: inc. Type II diabetes, hypoglycemia, hyperlipidemia, myocardial depression, bradycardia, reduced exercise tolerance, sleep disturbance and cold extremeties, impotence
- Contraindicated in: severe asthma, bradycardia, AV blockade, severe PVD, insulin dependent DM, Prinzmetal’s angina (may inc. vasospasm)
pindolol (Visken)
Non-selective Beta Antagonist
- blocks B1 receptors on myocardium and sinus node (can also dec. renin secretion)
- blocks B2 receptors leading to vasoconstriction and bronchospasm
- causes dec. HR and contractility
- used in CAD without signs of acute HF
- in combo with nitrates
- prolong survival in compensated HF d/t reduction of MVO2
- negative inotropic effects may worsen HF
- start with low dose and titrate slowly; rebound phenomenon if d/c’d abruptly d/t B1 receptor upregulation can cause unstable angina or MI (need to taper dosing)
- S/Fx: bronchospasm (avoid in asthmatics), poor outcomes: inc. Type II diabetes, hypoglycemia, hyperlipidemia, myocardial depression, bradycardia, reduced exercise tolerance, sleep disturbance and cold extremeties, impotence
- Contraindicated in: severe asthma, bradycardia, AV blockade, severe PVD, insulin dependent DM, Prinzmetal’s angina (may inc. vasospasm)
propranolol (Inderal)
Non-selective Beta Antagonist
- blocks B1 receptors on myocardium and sinus node (can also dec. renin secretion)
- blocks B2 receptors leading to vasoconstriction and bronchospasm
- causes dec. HR and contractility
- used in CAD without signs of acute HF
- in combo with nitrates
- prolong survival in compensated HF d/t reduction of MVO2
- negative inotropic effects may worsen HF
- start with low dose and titrate slowly; rebound phenomenon if d/c’d abruptly d/t B1 receptor upregulation can cause unstable angina or MI (need to taper dosing)
- S/Fx: bronchospasm (avoid in asthmatics), poor outcomes: inc. Type II diabetes, hypoglycemia, hyperlipidemia, myocardial depression, bradycardia, reduced exercise tolerance, sleep disturbance and cold extremeties, impotence
- Contraindicated in: severe asthma, bradycardia, AV blockade, severe PVD, insulin dependent DM, Prinzmetal’s angina (may inc. vasospasm)
avanafil (Stendra)
Phosphodiesterase 5 Inhibitor (PDE-5)Phosphodiesterase 5 inhibitors (PDE-5)
- inc. levels of cGMP (prevents cGMP conversion to GMP) and promotes modest drop in BP
- used in erectile dysfunction
- Onset: 15 min, Half-Life: 5-10 hr, nitrovasodilators contraindicated within 24 hrs
- S/Fx: can cause hypotension when used in combo with nitrates or alpha receptor blockers (excess cGMP and BP drop of >25 mmHg), HA, rhinitis, flushing, back pain, sudden loss of hearing, inc. loss of vision, blurred vision or loss of blue-green color discrimination
45-46 sildenafil (Viagra)
Phosphodiesterase 5 inhibitor (PDE-5)
- inc. levels of cGMP (prevents cGMP conversion to GMP) and promotes modest drop in BP
- used in erectile dysfunction and primary PHTN
- Onset: 1 hr, Half-Life: 3.7 hr, nitrovasodilators contraindicated within 24 hrs
- S/Fx: can cause hypotension when used in combo with nitrates or alpha receptor blockers (excess cGMP and BP drop of >25 mmHg), HA, rhinitis, flushing, back pain, sudden loss of hearing, inc. loss of vision, blurred vision or loss of blue-green color discrimination
tadalafil (Cialis)
Phosphodiesterase 5 inhibitor (PDE-5)
- inc. levels of cGMP (prevents cGMP conversion to GMP) and promotes modest drop in BP
- used in erectile dysfunction
- Onset: 15-30 min, Half-Life: 17.5 hr, nitrovasodilators contraindicated within 48 hrs
- S/Fx: can cause hypotension when used in combo with nitrates or alpha receptor blockers (excess cGMP and BP drop of >25 mmHg), HA, rhinitis, flushing, back pain, sudden loss of hearing, inc. loss of vision, blurred vision or loss of blue-green color discrimination
vardenafil (Levitra)
Phosphodiesterase 5 inhibitor (PDE-5)
- inc. levels of cGMP (prevents cGMP conversion to GMP) and promotes modest drop in BP
- used in erectile dysfunction
- Onset: 30-60 min, Half-Life: 3.3-3.9 hr, nitrovasodilators contraindicated within 24 hrs
- S/Fx: can cause hypotension when used in combo with nitrates or alpha receptor blockers (excess cGMP and BP drop of >25 mmHg), HA, rhinitis, flushing, back pain, sudden loss of hearing, inc. loss of vision, blurred vision or loss of blue-green color discrimination
isosorbide dinitrate
Nitrovasodilator
-increase cGMP
-reduce oxygen demand and increase oxygen supply
- 1st pass metabolism
-duration of action 3-5 hours, administered 3-4 times daily
-tolerance/tachphylaxis
-side effects: headache, orthostatic hypotension, dizziness, flushing, syncope, reflex tachycardia, GI distress, skin irritation (patch)
contraindicated with PDE-5 inhibitors
isosorbide monoitrate
Nitrovasodilator -increase cGMP -reduce oxygen demand and increase oxygen supply -minimal 1st pass metabolism -longer duration of action -tolerance/tachphylaxis -side effects: headache, orthostatic hypotension, dizziness, flushing, syncope, reflex tachycardia, GI distress, skin irritation (patch) contraindicated with PDE-5 inhibitors
nitroglycerin
Nitrovasodilator
-increase cGMP
-reduce oxygen demand and increase oxygen supply
- 1st pass metabolism
-duration of action dependent on formulation
-tolerance/tachphylaxis
-side effects: headache, orthostatic hypotension, dizziness, flushing, syncope, reflex tachycardia, GI distress, skin irritation (patch)
contraindicated with PDE-5 inhibitors
nitroprusside sodium
direct vasodilator
- generates NO which activates guanyly cyclase, increase cGMP
- effect on veins and arteries to reduce preload and afterload
- use: produce hypotension in surgery and hypertensive emergencies
- adverse effects- rapid decrease in MAP, cyanide accumulation (infusion >48 hours and/or impaired renal function)
aspirin
- inhibits the synthesis of thromboxane A2 by irreversible acetylation of cyclooxygenase
- used to help reduce TIA, stroke, MI, ACS
- side effects- excessive bleeding
clopidogrel
thienopyridine
- ADP antagonists at P2Y-12 receptor
- block ADP mediated activation of glycoprotein GPIIb/IIIa
- prevents platelet aggregation
- use in combination with aspirin in ACS, MI, and stroke
- side effects- neutropenia
- genetic variability in metabolism